AJP - Renal Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 295: F1295-F1300, 2008. First published August 27, 2008; doi:10.1152/ajprenal.90407.2008
0363-6127/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/5/F1295    most recent
90407.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krag, A.
Right arrow Articles by Møller, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krag, A.
Right arrow Articles by Møller, S.

TRANSLATIONAL PHYSIOLOGY

Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects

Aleksander Krag,1,2 Flemming Bendtsen,1 Erling Bjerregaard Pedersen,3 Niels-Henrik Holstein-Rathlou,4 and Søren Møller2

Departments of 1Gastroenterology and 2Clinical Physiology, Hvidovre University Hospital, Faculty of Health Sciences, University of Copenhagen, Hvidovre; 3Department of Medical Research and Department of Medicine, Holstebro Hospital, Holstebro; and 4Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Submitted 11 July 2008 ; accepted in final form 20 August 2008

The vasopressin analog terlipressin is believed to cause vasoconstriction selectively by V1 receptor stimulation. However, a possible antidiuretic effect by V2 receptor stimulation has never been ruled out. Twenty-two patients with ascites, including seven with refractory ascites, were included. The subjects were studied during a 400 ml/h oral water load before and after infusion of 2 mg of terlipressin (18 patients) or placebo infusion (4 patients). Effects on the V2 receptors were assessed by evaluating aquaporin (AQP)2 excretion, free water clearance (CFormula), urine osmolality (Uosm), and fractional distal water excretion (DFeH2O). After terlipressin the excretion of AQP2 increased by 89% [144 ng/mmol creatinine, 95% confidence interval (CI) 73–214 ng/mmol creatinine, P = 0.001]. CFormula decreased 1.05 ml/min (from 0.17 to –0.89 ml/min, P = 0.001), and DFeH2O decreased 37% (19 vs. 12; 95% CI 2–11, P = 0.01). Uosm increased by 27% (93 mosmol/kgH2O, 95% CI 23–164 mosmol/kgH2O, P = 0.02). Plasma sodium decreased 1.1 mmol/l (P < 0.01). An increase in AQP2 excretion and a decrease in CFormula and distal water excretion after terlipressin despite water loading is a clear indication of activation of the antidiuretic system (V2 receptor effect).

aquaporin-2; vasopressin; hepatorenal syndrome; cirrhosis; ascites



Address for reprint requests and other correspondence: A. Krag, Dept. of Gastroenterology 439, Hvidovre University Hospital, DK-2650 Hvidovre, Denmark (e-mail: aleksander.krag{at}hvh.regionh.dk)




This article has been cited by other articles:


Home page
Therapeutic Advances in GastroenterologyHome page
W. A. Hackworth and A. J. Sanyal
Review: Vasoconstrictors for the treatment of portal hypertension
Therapeutic Advances in Gastroenterology, March 1, 2009; 2(2): 119 - 131.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.